Clinical Trial Update: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) [Phase 1]

View source ↗

Summary

Phase 1 single rising dose study of MK-8723 in healthy participants and patients with immune thrombocytopenia purpura has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia Purpura

Drugs mentioned

• MK-8723

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Immune Thrombocytopenia Purpura | Phase 1 | Status: COMPLETED | Results posted: 2017-03-21